CSL's Total Assets for the quarter that ended in Dec. 2025 was $37,902 Mil.
Warning Sign:
If a company builds assets at 27.9% a year, faster than its revenue growth rate of 12.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, CSL's average Total Assets Growth Rate was 1.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 30.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 23.60% per year.
During the past 13 years, CSL's highest 3-Year average Total Assets Growth Rate was 56.70%. The lowest was -0.60%. And the median was 16.65%.
Total Assets is connected with ROA %. CSL's annualizedROA % for the quarter that ended in Dec. 2025 was 2.07%. Total Assets is also linked to Revenue through Asset Turnover. CSL's Asset Turnover for the quarter that ended in Dec. 2025 was 0.21.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
CSL's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
CSL Total Assets Related Terms
CSL Total Assets Historical Data
* Premium members only.
The historical data trend for CSL's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
CSL's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (CSLLY) has a Total Assets of $37,902 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on CSL and its competitors.
Is CSL's Total Assets too high?
CSL's current Total Assets is $37,902 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Total Assets compare to VRTX and REGN?
CSL's Total Assets of $37,902 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CSL and its competitors. CSL's current Total Assets is $37,902 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current Total Assets is $37,902 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CSL (CSLLY), the current Total Assets is $37,902 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Total Assets: $37,902 Mil
GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
